1 エグゼクティブ・サマリー
2 序文
2.1 概要
2.2 ステークホルダー
2.3 調査範囲
2.4 調査方法
2.4.1 データマイニング
2.4.2 データ分析
2.4.3 データの検証
2.4.4 リサーチアプローチ
2.5 リサーチソース
2.5.1 一次調査ソース
2.5.2 セカンダリーリサーチソース
2.5.3 前提条件
3 市場動向分析
3.1 はじめに
3.2 推進要因
3.3 抑制要因
3.4 機会
3.5 脅威
3.6 エンドユーザー分析
3.7 新興市場
3.8 Covid-19の影響
4 ポーターズファイブフォース分析
4.1 供給者の交渉力
4.2 買い手の交渉力
4.3 代替品の脅威
4.4 新規参入の脅威
4.5 競争上のライバル関係
5 椎間板変性疾患治療の世界市場（タイプ別
5.1 はじめに
5.2 従来の薬剤
5.2.1 アセトアミノフェン
5.2.2 非ステロイド性抗炎症薬（NSAIDs）
5.2.3 副腎皮質ステロイド薬
5.2.4 筋弛緩薬
5.2.5 オピオイド
5.3 新規治療薬
5.3.1 細胞療法
5.3.2 多血小板血漿（PRP）
5.4 その他のタイプ
6 椎間板変性疾患治療の世界市場（治療タイプ別
6.1 導入
6.2 作業療法
6.3 理学療法
6.4 特別な運動
6.5 薬物療法
6.6 減量手術
6.7 その他の治療タイプ
7 椎間板変性疾患治療の世界市場：投与経路別
7.1 導入
7.2 経口剤
7.3 注射剤
8 椎間板変性疾患治療の世界市場：エンドユーザー別
8.1 はじめに
8.2 病院
8.3 診療所
8.4 その他のエンドユーザー
9 椎間板変性疾患治療の世界市場：地域別
9.1 はじめに
9.2 北米
9.2.1 アメリカ
9.2.2 カナダ
9.2.3 メキシコ
9.3 ヨーロッパ
9.3.1 ドイツ
9.3.2 イギリス
9.3.3 イタリア
9.3.4 フランス
9.3.5 スペイン
9.3.6 その他のヨーロッパ
9.4 アジア太平洋
9.4.1 日本
9.4.2 中国
9.4.3 インド
9.4.4 オーストラリア
9.4.5 ニュージーランド
9.4.6 韓国
9.4.7 その他のアジア太平洋地域
9.5 南米
9.5.1 アルゼンチン
9.5.2 ブラジル
9.5.3 チリ
9.5.4 その他の南米地域
9.6 中東・アフリカ
9.6.1 サウジアラビア
9.6.2 アラブ首長国連邦
9.6.3 カタール
9.6.4 南アフリカ
9.6.5 その他の中東・アフリカ地域
10 主要開発
10.1 契約、パートナーシップ、提携、合弁事業
10.2 買収と合併
10.3 新製品上市
10.4 拡張
10.5 その他の主要戦略
11 企業プロフィール
Novartis AG
Eli Lilly and Company
AstraZeneca Plc
Spine BioPharma Inc.
Medtronic plc
DiscGenics, Inc.
Johnson & Johnson Services, Inc.
Abbott Laboratories
Stryker
Ferring B.V.
Pfizer Inc.
Globus Medical, Inc.
B. Braun Melsungen AG
Ensol Biosciences Inc.
Zimmer Biomet Holdings, Inc.
表一覧
表1 椎間板変性疾患治療の世界市場展望：地域別（2022-2030年） ($MN)
表2 椎間板変性疾患治療の世界市場展望：タイプ別（2022-2030年） ($MN)
表3 椎間板変性疾患治療の世界市場展望：従来型薬剤別（2022-2030年） ($MN)
表4 椎間板変性疾患治療の世界市場展望：アセトアミノフェン別 (2022-2030) ($MN)
表5 椎間板変性疾患治療の世界市場展望：非ステロイド性抗炎症薬（NSAIDs）別 (2022-2030) ($MN)
表6 椎間板変性疾患治療の世界市場展望：副腎皮質ステロイド薬別 (2022-2030) ($MN)
表7 椎間板変性疾患治療の世界市場展望：筋弛緩薬別 (2022-2030) ($MN)
表8 椎間板変性疾患治療の世界市場展望：オピオイド別 (2022-2030) ($MN)
表9 椎間板変性疾患治療の世界市場展望：新規治療薬別（2022-2030年） ($MN)
表10 椎間板変性疾患治療の世界市場展望：細胞療法別 (2022-2030) ($MN)
表11 椎間板変性疾患治療の世界市場展望：血小板豊富血漿（PRP）別 (2022-2030) ($MN)
表12 椎間板変性疾患治療の世界市場展望：その他のタイプ別 (2022-2030) ($MN)
表13 椎間板変性疾患治療の世界市場展望：治療タイプ別 (2022-2030) ($MN)
表14 椎間板変性疾患治療の世界市場展望：作業療法別 (2022-2030) ($MN)
表15 椎間板変性疾患治療の世界市場展望：理学療法別 (2022-2030) ($MN)
表16 椎間板変性疾患治療の世界市場展望：特殊運動別 (2022-2030) ($MN)
表17 椎間板変性疾患治療の世界市場展望：薬物療法 (2022-2030年) ($MN)
表18 椎間板変性疾患治療の世界市場展望：減量手術別 (2022-2030) ($MN)
表19 椎間板変性疾患治療の世界市場展望：その他の治療タイプ別 (2022-2030) ($MN)
表20 椎間板変性疾患治療の世界市場展望：投与経路別（2022-2030年） ($MN)
表21 椎間板変性疾患治療の世界市場展望：経口剤別 (2022-2030) ($MN)
表22 椎間板変性疾患治療の世界市場展望：注射剤別 (2022-2030) ($MN)
表23 椎間板変性疾患治療の世界市場展望：エンドユーザー別 (2022-2030) ($MN)
表24 椎間板変性疾患治療の世界市場展望：病院別 (2022-2030) ($MN)
表25 椎間板変性疾患治療の世界市場展望：診療所別（2022-2030年） ($MN)
表26 椎間板変性疾患治療の世界市場展望：その他のエンドユーザー別 (2022-2030) ($MN)
注：北米、ヨーロッパ、APAC、南米、中東・アフリカ地域の表も上記と同様に表記しています。
According to the National Institutes of Health (NIH), nearly 80% of people experience low back pain at some point in their lives, and degenerative disc disease is a common cause of this pain.
Market Dynamics:
Driver:
Increased frequency of immune conditions
Degenerative disc diseases are known to be influenced by the rising incidence of autoimmune disorders. DDD symptoms may worsen as a result of inflammation and degeneration of the spinal structures caused by diseases like rheumatoid arthritis. Patients in need of specialized treatment for DDD are increasing in number as autoimmune diseases become more prevalent worldwide, partly as a result of environmental factors and changes in lifestyle. Additionally, this pattern highlights the requirement for integrated care strategies that deal with degenerative disc problems and autoimmune diseases concurrently.
Restraint:
Exorbitant surgical intervention costs
The high expense of surgical procedures for degenerative disc disease, such as discectomy, spinal fusion, and artificial disc replacement, can prevent patients from receiving these treatments. Due to insufficient insurance coverage or high out-of-pocket costs for these procedures, many people encounter financial difficulties. Potential market growth may be limited if patients are discouraged from seeking necessary surgical interventions due to financial burdens. Furthermore, patients may be deterred from pursuing surgical solutions by post-surgical complications like bleeding, nerve damage, and inflammation because they are afraid of the unfavorable results.
Opportunity:
Raising patient involvement and awareness
Due to the efforts and educational campaigns of healthcare providers, there is a growing public awareness of degenerative disc disease and spine health. People are encouraged to seek medical attention for DDD symptoms early in the disease's progression as a result of this increased awareness. The demand for different treatment modalities rises in tandem with patients increased proactivity in maintaining their spinal health. Moreover, through community outreach initiatives, support groups, and educational materials, this trend gives healthcare organizations and providers a chance to interact with patients and ultimately improve patient outcomes and satisfaction.
Threat:
Market saturation and intense competition
There is fierce competition in the DDD treatment market from many players providing a variety of treatment options, ranging from cutting-edge surgical interventions to conservative therapies. Price wars resulting from this saturation may lower manufacturer’s profit margins and deter investment in R&D. Furthermore, differentiation gets harder as more businesses enter the market with comparable products, which could cause market fragmentation. To stay competitive, businesses must constantly innovate, which can be risky and resource-intensive.
Covid-19 Impact:
The market for treatments for Degenerative Disc Disease (DDD) has been severely impacted by the COVID-19 pandemic, mainly as a result of the reallocation of medical resources and the disruption of healthcare services. Many elective surgeries, including those for degenerative disc disease, were cancelled or postponed as hospitals and clinics concentrated on managing COVID-19 cases. Patients requiring surgical care for spinal conditions experienced severe delays as a result. Additionally, reducing demand for DDD treatments was a shift in patient behaviour brought about by the pandemic. Many people were reluctant to seek in-person medical care because they were afraid of spreading the virus.
The Occupational Therapy segment is expected to be the largest during the forecast period
The segment with the largest share is occupational therapy. This strategy aims to enhance people's quality of life and assist them in managing their everyday activities in spite of the limitations imposed by degenerative disc disease. Personalized treatment plans, including functional training, adaptive strategies, and ergonomic evaluations to lessen spinal strain, are commonly used in occupational therapy for DDD patients. Moreover, therapists collaborate with patients to create pain management plans, improve mobility, and improve day-to-day functioning. Occupational therapy has become more popular as a result of the growing understanding of the value of comprehensive and patient-centered care in the management of chronic conditions.
The Hospitals segment is expected to have the highest CAGR during the forecast period
Over the course of the forecast period, the hospital segment is anticipated to show the highest CAGR. This growth is explained by the growing number of hospitals with specialized departments that are outfitted with cutting-edge diagnostic equipment and treatment plans designed specifically to manage degenerative disc diseases. In order to treat DDD effectively, hospitals offer a wide range of services, such as physical therapy, pain management, and surgical interventions. Furthermore, the incorporation of state-of-the-art technologies, like minimally invasive surgical methods and improved imaging capacities, adds to hospitals attractiveness as the principal treatment destinations for individuals with spinal disorders.
Region with largest share:
The market for treatments for degenerative disc disease (DDD) is dominated by the North American region. The primary reasons for this dominance are the high prevalence of degenerative disc disease and chronic back pain in the population, as well as a robust healthcare system that makes access to state-of-the-art treatment options possible. The region's healthcare system is distinguished by large expenditures on R&D, which result in the acceptance of cutting-edge treatments and tools for DDD management. Additionally, there is a growing trend of major market players merging and acquiring one another, which increases the availability of innovative treatment options.
Region with highest CAGR:
Over the course of the forecast period, the Degenerative Disc Disease (DDD) Treatment Market is expected to grow at the highest CAGR in the Asia-Pacific region. The population's increased occurrence of degenerative diseases and chronic low back pain, along with rising healthcare expenditures targeted at enhancing treatment accessibility, are some of the factors contributing to this growth. Effective DDD treatments are in greater demand as nations in this region improve their diagnostic and therapeutic capacities as well as their healthcare infrastructure. Moreover, driving market growth is anticipated to come from market participants' attempts to obtain regulatory approvals for novel therapies and clinical trials in countries such as South Korea and Japan.
Key players in the market
Some of the key players in Degenerative Disc Disease Treatment market include Novartis AG, Eli Lilly and Company, AstraZeneca Plc, Spine BioPharma Inc., Medtronic plc, DiscGenics, Inc., Johnson & Johnson Services, Inc., Abbott Laboratories, Stryker, Ferring B.V., Pfizer Inc., Globus Medical, Inc., B. Braun Melsungen AG, Ensol Biosciences Inc. and Zimmer Biomet Holdings, Inc.
Key Developments:
In July 2024, Spine BioPharma, Inc., a company committed to developing non-opiate, non-surgical therapies for the treatment of pain related disabilities, announced that it has signed an agreement with Korean Company Ensol BioSciences, Inc. to expand the indications of its therapeutic drug treatment candidate, SB-01 For Injection.
In June 2024, Novartis has entered an agreement to make a voluntary public takeover offer to acquire MorphoSys AG, a Germany-based, global biopharmaceutical company developing oncology medicines, for €2.7 billion. The acquisition, subject to customary closing conditions, further expands Novartis’ oncology pipeline as well as its global footprint in hematology.
In May 2024, AstraZeneca has entered a worldwide licence and option agreement with Nona Biosciences for a preclinical monoclonal antibody. The deal focuses on the development of the antibody to develop targeted tumour therapies. Nona is eligible to receive $19m from AstraZeneca upon completion of the deal.
Types Covered:
• Conventional Drugs
• Novel Therapies
• Other Types
Treatment Types Covered:
• Occupational Therapy
• Physical Therapy
• Special Exercises
• Medications
• Weight Loss Surgery
• Other Treatment Types
Route of Administrations Covered:
• Oral
• Injectable
End Users Covered:
• Hospitals
• Clinics
• Other End Users
Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Degenerative Disc Disease Treatment Market, By Type
5.1 Introduction
5.2 Conventional Drugs
5.2.1 Acetaminophen
5.2.2 Non-steroidal Anti-inflammatory Drugs (NSAIDs)
5.2.3 Corticosteroids
5.2.4 Muscle Relaxants
5.2.5 Opioids
5.3 Novel Therapies
5.3.1 Cell Therapy
5.3.2 Platelet Rich Plasma (PRP)
5.4 Other Types
6 Global Degenerative Disc Disease Treatment Market, By Treatment Type
6.1 Introduction
6.2 Occupational Therapy
6.3 Physical Therapy
6.4 Special Exercises
6.5 Medications
6.6 Weight Loss Surgery
6.7 Other Treatment Types
7 Global Degenerative Disc Disease Treatment Market, By Route of Administration
7.1 Introduction
7.2 Oral
7.3 Injectable
8 Global Degenerative Disc Disease Treatment Market, By End User
8.1 Introduction
8.2 Hospitals
8.3 Clinics
8.4 Other End Users
9 Global Degenerative Disc Disease Treatment Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Novartis AG
11.2 Eli Lilly and Company
11.3 AstraZeneca Plc
11.4 Spine BioPharma Inc.
11.5 Medtronic plc
11.6 DiscGenics, Inc.
11.7 Johnson & Johnson Services, Inc.
11.8 Abbott Laboratories
11.9 Stryker
11.10 Ferring B.V.
11.11 Pfizer Inc.
11.12 Globus Medical, Inc.
11.13 B. Braun Melsungen AG
11.14 Ensol Biosciences Inc.
11.15 Zimmer Biomet Holdings, Inc.
List of Tables
Table 1 Global Degenerative Disc Disease Treatment Market Outlook, By Region (2022-2030) ($MN)
Table 2 Global Degenerative Disc Disease Treatment Market Outlook, By Type (2022-2030) ($MN)
Table 3 Global Degenerative Disc Disease Treatment Market Outlook, By Conventional Drugs (2022-2030) ($MN)
Table 4 Global Degenerative Disc Disease Treatment Market Outlook, By Acetaminophen (2022-2030) ($MN)
Table 5 Global Degenerative Disc Disease Treatment Market Outlook, By Non-steroidal Anti-inflammatory Drugs (NSAIDs) (2022-2030) ($MN)
Table 6 Global Degenerative Disc Disease Treatment Market Outlook, By Corticosteroids (2022-2030) ($MN)
Table 7 Global Degenerative Disc Disease Treatment Market Outlook, By Muscle Relaxants (2022-2030) ($MN)
Table 8 Global Degenerative Disc Disease Treatment Market Outlook, By Opioids (2022-2030) ($MN)
Table 9 Global Degenerative Disc Disease Treatment Market Outlook, By Novel Therapies (2022-2030) ($MN)
Table 10 Global Degenerative Disc Disease Treatment Market Outlook, By Cell Therapy (2022-2030) ($MN)
Table 11 Global Degenerative Disc Disease Treatment Market Outlook, By Platelet Rich Plasma (PRP) (2022-2030) ($MN)
Table 12 Global Degenerative Disc Disease Treatment Market Outlook, By Other Types (2022-2030) ($MN)
Table 13 Global Degenerative Disc Disease Treatment Market Outlook, By Treatment Type (2022-2030) ($MN)
Table 14 Global Degenerative Disc Disease Treatment Market Outlook, By Occupational Therapy (2022-2030) ($MN)
Table 15 Global Degenerative Disc Disease Treatment Market Outlook, By Physical Therapy (2022-2030) ($MN)
Table 16 Global Degenerative Disc Disease Treatment Market Outlook, By Special Exercises (2022-2030) ($MN)
Table 17 Global Degenerative Disc Disease Treatment Market Outlook, By Medications (2022-2030) ($MN)
Table 18 Global Degenerative Disc Disease Treatment Market Outlook, By Weight Loss Surgery (2022-2030) ($MN)
Table 19 Global Degenerative Disc Disease Treatment Market Outlook, By Other Treatment Types (2022-2030) ($MN)
Table 20 Global Degenerative Disc Disease Treatment Market Outlook, By Route of Administration (2022-2030) ($MN)
Table 21 Global Degenerative Disc Disease Treatment Market Outlook, By Oral (2022-2030) ($MN)
Table 22 Global Degenerative Disc Disease Treatment Market Outlook, By Injectable (2022-2030) ($MN)
Table 23 Global Degenerative Disc Disease Treatment Market Outlook, By End User (2022-2030) ($MN)
Table 24 Global Degenerative Disc Disease Treatment Market Outlook, By Hospitals (2022-2030) ($MN)
Table 25 Global Degenerative Disc Disease Treatment Market Outlook, By Clinics (2022-2030) ($MN)
Table 26 Global Degenerative Disc Disease Treatment Market Outlook, By Other End Users (2022-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
